Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AntibioticeBSE:ATB +0.48%78 EV-to-EBIT is 102.13 as of Aug. 22, 2026, which is 709% above its 10-year median of 12.63. GuruFocus rates BSE:ATB with a GF Score™ of 78/100 and a GF Value™ of lei2.18 (Fairly Valued). The stock has 7 warning signs investors should review. Among 690 Drug Manufacturers companies, Antibiotice ranks worse than 94.2% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Antibiotice's Enterprise Value for the quarter that ended in Jun. 2026 was lei1,800.3 Mil.
Antibiotice's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei17.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Antibiotice EV-to-EBIT Related Terms
Antibiotice EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Antibiotice's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Antibiotice's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Antibiotice EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Antibiotice's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Antibiotice's EV-to-EBIT falls into.
Antibiotice's current Enterprise Value is lei1,763.4 Mil.
Antibiotice's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was lei17.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Antibiotice (BSE:ATB) has a EV-to-EBIT of 102.13 as of Aug. 22, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Antibiotice and its competitors. This is 709% above median its historical median of 12.63. Over the past decade, Antibiotice's EV-to-EBIT has ranged from 5.22 to 104.55. According to the industry distribution chart, Antibiotice ranks #650 out of 690 companies in the Drug Manufacturers industry, placing it in the top 94.2%.
Is Antibiotice's EV-to-EBIT too high?
Antibiotice's current EV-to-EBIT of 102.13 is 709% above median its 10-year median of 12.63. Over the past 10 years, this metric has ranged from a low of 5.22 to a high of 104.55. The Drug Manufacturers industry median EV-to-EBIT is 15.12. Antibiotice's value of 102.13 is 575.7% above this industry median. Based on the distribution chart, Antibiotice ranks #650 out of 690 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Antibiotice has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Antibiotice's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Antibiotice ranks #650 out of 690 companies for EV-to-EBIT. This places Antibiotice in the lower half of its industry. The industry median EV-to-EBIT is 15.12. Antibiotice's value of 102.13 is 575.7% above this benchmark. Historically, Antibiotice's own EV-to-EBIT has ranged from 5.22 to 104.55 over the past decade. While the company's 10-year median is 12.63 vs. the industry median of 15.12, Antibiotice has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.12, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Antibiotice's current EV-to-EBIT of 102.13 is 575.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Antibiotice and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Antibiotice's current EV-to-EBIT is 102.13, which is 709% above median its own 10-year median of 12.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Antibiotice stock overvalued right now?
Based on GuruFocus' analysis, Antibiotice (BSE:ATB) is currently considered Fairly Valued. The stock's GF Value™ is lei2.18, compared to a current price of lei2.11 — trading 3.2% below its estimated fair value. The current EV-to-EBIT is 102.13, which is 709% above median its 10-year median of 12.63 and 575.7% above the Drug Manufacturers industry median of 15.12. Antibiotice's overall GF Score™ is 78/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Antibiotice (BSE:ATB), the current EV-to-EBIT is 102.13 as of Aug. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Antibiotice (BSE:ATB) Overvalued in 2026?
Based on GuruFocus' analysis, Antibiotice stock appears to be undervalued.
The current stock price of lei2.11 is trading 3.2% below its estimated GF Value™ of lei2.18.
GuruFocus considers Antibiotice to be Fairly Valued.
Key valuation signals for BSE:ATB:
EV-to-EBIT: 102.13 (709% above median its 10-year median of 12.63)
GF Value™: lei2.18 vs. price of lei2.11 (3.2% below fair value)
Industry Position: 575.7% above the Drug Manufacturers median (#650 of 690)
No single metric tells the full story. See the BSE:ATB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Antibiotice SA is a Romania based company engaged in manufacturing generic medicines. It primarily develops and produces generic medicines for human use, veterinary medicines and active substance Nystatin. The group's generic medicines are primarily targeted at patients with infections, dermatological, cardiovascular, digestive tract diseases or diseases of the musculoskeletal system. It manufactures firm powders for solutions for injection and suspensions for injection (penicillins), capsules, tablets, suppositories and topical preparations (ointments, gels, creams).
78GF Score
Get the complete analysis for BSE:ATB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSE:ATB has been successfully added to your 
